Net Asset Value(s)
Updated : 12:09
This regulatory news is for Private Investors only
RNS Number : 5440I
European Opportunities Trust PLC
27 March 2024
European Opportunities Trust PLC
27 March 2024
The Company announces the following unaudited estimates as at Valuation 26 March 2024:
| Total Assets | excluding current year income and expenses | £653.631 million |
| including current year income and expenses | £652.555 million | |
| Net asset value per Ordinary share | excluding current year income and expenses | 991.12p |
| including current year income and expenses | 989.48p |
A monthly fact sheet and copies of the company's most recent interim and full annual reports and
accounts are available for download from www.devonem.com and on request from:
Richard Pavry
Devon Equity Management Limited, company secretaries to European Opportunities Trust PLC
enquiries@devonem.com
020 3985 0445
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.